Liquidia (NASDAQ:LQDA) Stock: Insider Dana Boyle Sells 5,892 Shares

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 5,892 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $167,804.16. Following the transaction, the chief accounting officer directly owned 165,609 shares of the company’s stock, valued at $4,716,544.32. This represents a 3.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 27th, Dana Boyle sold 1,600 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total transaction of $140,048.00.

Liquidia Stock Performance

Shares of LQDA stock opened at $33.94 on Thursday. The company’s fifty day simple moving average is $62.30 and its 200-day simple moving average is $61.74. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The firm has a market cap of $3.04 billion, a PE ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a 12 month low of $21.94 and a 12 month high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.49) EPS. Equities research analysts expect that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. The Manufacturers Life Insurance Company raised its position in Liquidia by 63.3% during the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after acquiring an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Liquidia in the second quarter valued at $29,694,000. Seven Fleet Capital Management LP grew its position in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after acquiring an additional 51,727 shares during the period. Bank of America Corp DE grew its position in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the period. Finally, Handelsbanken Fonder AB bought a new position in shares of Liquidia in the 2nd quarter valued at about $1,993,000. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LQDA shares. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Lifesci Capital upgraded Liquidia from a “market perform” rating to an “outperform” rating and set a $59.00 price objective for the company in a report on Wednesday. Bank of America lifted their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Finally, Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $77.31.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
• Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
• Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
• Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
• Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).